# SARS-CoV-2 Spike glycoprotein [mRNA]

## Pfizer-BioNTech (5-11y/o) 0.2mL/dose (1.3mL/vial)

| TAH Drug Code      | [IBNT1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBNT1)                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 5 through 11 Years of Age                          |
| Dosing             | IM, 0.2 mL, 5-11 years old, 2-dose series separated by at least 3 weeks                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                        |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy          | Unknown                                                                                                                                      |
| Lactation          | Unknown                                                                                                                                      |

## Pfizer-BioNTech (6M-4歲) 0.2mL/dose (0.4mL/vial)

| TAH Drug Code      | [IBNT6M](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBNT6M)                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 months to 4 Years of Age                                                                                                                                                                         |
| Dosing             | 6 months to 4 years: Primary series, 0.2 mL IM for 2 doses, administered 3 weeks apart, followed by a third dose (0.2 mL) administered at least 8 weeks after the second dose.                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                                                                                                                                                                        |
| Adverse Effects    | Common Dermatologic: Erythema at injection site, Injection site pain, Swelling at injection site. Musculoskeletal: Arthralgia, Myalgia. Neurologic: Headache. Other: Fatigue, Fever, Shivering. Serious Gastrointestinal: Appendicitis. Immunologic: Anaphylaxis, Hypersensitivity reaction. |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                      |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                      |

## BA1雙價Moderna(Covid19) 0.5mL/dose(2.5mL/vial)

| TAH Drug Code      | [ICOMDBA1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOMDBA1)                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                                                                |
| Dosing             | IM, 0.5 mL, > or = 18 years, As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine, bivalent Original/Omicron BA.1 which contains elasomeran and an additional mRNA molecule. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                  |
| Contraindications  | Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.                                         |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea.                                                                                   |
| Pregnancy          | Unknown                                                                                                                                                                                                                        |
| Lactation          | Unknown                                                                                                                                                                                                                        |

## BA4/5次世代Moderna(Covid19) 0.5mL/dose(2.5mL/vial)

| TAH Drug Code      | [ICOMDBA5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOMDBA5)                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                                                                  |
| Dosing             | IM, 0.5 mL, > or = 18 years, As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine, bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                    |
| Contraindications  | History of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.                                                                                                                      |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea.                                                                                     |
| Pregnancy          | Unknown                                                                                                                                                                                                                          |
| Lactation          | Unknown                                                                                                                                                                                                                          |

## COVID-19 Vaccine BioNTech 0.3mL/dose (0.45mL/vial)

| TAH Drug Code      | [ICOVBNT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOVBNT)                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | BioNTech COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 12 years of age and older.                             |
| Dosing             | IM, 0.3 mL, > or = 18 years 2 doses administered 3 weeks apart. (Taiwan CDC suggests 2 doses administered 4 weeks apart.)                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                        |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy          | Unknown                                                                                                                                      |
| Lactation          | Unknown                                                                                                                                      |

## COVID-19 Vaccine Moderna 0.5mL/dose (5mL/vial)

| TAH Drug Code      | [ICOVMDN](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOVMDN)                                                                                                             |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                        |
| Dosing             | IM, 0.5 mL, > or = 18 years 2 doses administered 28 days apart.                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                          |
| Contraindications  | Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine. |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea.                                           |
| Pregnancy          | Unknown                                                                                                                                                                                |
| Lactation          | Unknown                                                                                                                                                                                |

